A Quality by Design (QbD) Based Method Development and Validation of a High-Performance Liquid Chromatography for the Simultaneous Estimation of Metformin and Ertugliflozin
Article Sidebar
-
Quality by Design, Design of Experiments, Metformin, Ertugliflozin and Analytical Target Profile
Abstract
This study explains about the Analytical Quality by Design approach for the optimization of a High-Performance Liquid Chromatography Method for the simultaneous estimation of Metformin and Ertugliflozin in pharmaceutical substance. The study aimed to optimize the High-Performance Liquid Chromatography (HPLC) by means of an analytical target profile in order to achieve good separation of compounds along with acceptable analysis time. Identification of risk factors for variables affects the method efficacy. This leads to the development of an accurate, precise, and economic method. The optimized conditions of the developed method were a stationary phase of a Discovery C18 250 x 4.6mm, 5m and a mobile phase of Orthophosphoric acid buffer (pH 2.2), ACN taken in the ratio 60:40 was selected as mobile phase and detection wavelength of 230nm. The flow rate was selected as 0.98ml/min at 29.150C column temperature. Using the central composite design (CCD) method was optimized. The method is showing the linearity over the concentration range of 25-150µg/ml for Metformin and 0.375-2.25µg/ml for Ertugliflozin. The intra-and inter-day precision were less than 2% of relative standard deviation. Accuracies between 99-102% of the true values. The LOD obtained for Metformin and Ertugliflozin were found to be 59 and 3.7, respectively. LOQ obtained for Metformin and Ertugliflozin were 77.6 and 5.2, respectively. Under accelerated conditions degradation percentage of the drug was found to be less than 10%, and the degradation product peak not affecting the system suitability of Metformin and Ertugliflozin.
Full text article
References
Cinti, F., Moffa, S., Impronta, F., Cefalo, C. M., Sun, V. A., Sorice, G. P., Qiaccari, A. 2017. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug design, development and therapy, 11:2905–2919.
ICH Q8 (R2) 2009. Guidance for Industry Q8(R2) Pharmaceutical Development. [Accessed on 15.01.2018]. Food and Drug Administration, pages 1–29.
ICH Q9 2005. Harmonised Tripartite Guideline Quality risk management, Sep 2005. International conference on harmonisation of technical Requirements for registration of pharmaceuticals for human Use, pages 1–23.
Kumari, K. S., Bandhakavi, S. 2020. Development and validation of stability-indicating RP- HPLC method for the simultaneous determination of ertugliflozin pidolate and metformin hydrochloride in bulk and tablets. Future Journal of Pharmaceutical Sciences, 6(1):1–10.
Laxmi, M. R. V., Vallikumari, S., Marakatham, M. S., Kumar 2019. RP-HPLC method development and validation for simultaneous estimation of ertugliflozin and sitagliptin in bulk and tablet dosage forms. Indian Journal of Applied Research, 9(10):9–13.
Nizami, T., Shrivastava, B., Sharma, P. 2018. Analytical method development and validation for simultaneous estimation of Ertugliflozin and Metformin in tablet dosage form by RP-HPLC method. International Journal of Pharmacy and Life Sciences, 9:5854–5859.
Peraman, R., Bhadraya, K., Reddy, Y. P. 2015. Analytical Quality by Design: A Tool for Regulatory Flexibility and Robust Analytics. International Journal of Analytical Chemistry, 2015:1–9.
Raman, N. V. V. S. S., Mallu, U. R., Bapatu, H. R. 2015. Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing. Journal of Chemistry, 2015:1–8.
Rao, P. V., Rao, L., Svum, P. 2019. Development and validation of new stability-indicating Reversed- Phase High-Performance Liquid Chromatography method for simultaneous determination of metformin hydrochloride and ertugliflozin in a bulk and pharmaceutical dosage form. Asian journal of pharmaceutical and clinical research, 12(1):235– 240.
Reid, G. L., Morgado, J., Barnett, K., Harrington, B., Wang, J., Harwood, J., Fortin, D. 2013. Analytical Quality by Design (AQbD) in Pharmaceutical Development. American Pharmaceutical Review, 16(5).
Setter, S. M., Iltz, J. L., Thams, J., Campbell, R. K. 2003. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy. Clinical Therapeutics, 25(12):2991–3026.
Shafaat, S. W., Ahmed, A., Khan, G. J., Anas, S., Qureshi, A. A. 2020. Analytical method development and validation for simultaneous estimation of ertugliflozin and metformin hcl in bulk and pharmaceutical dosage form by HPLC. International Journal of Pharmaceutical Sciences and Research, 11(1):226–232.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.